Analyze any stock

CANF

Can-Fite BioPharma Ltd.

Last price

$3.23

●Trend Score?

0/4

●Stretch Score?

2/6

Regime: DowntrendVolatility: NormalOversold-leaning

Chart Summary

CANF is showing weaker bearish structure with some mixed stretch signals. RSI is 48.6 and neutral.

As of 2026-07-16 15:30:14 · Source: financialmodelingprep.com

Breakdown

?Learn more →

MA200

-36.68%

VWMA(20)

-20.46%

Stoch

Oversold

Earnings

Weak

ATR

Normal 1.10×

MACD

Bearish

RSI

Neutral

Volume

Normal 0.00×

Price · Overview

From 2026-03-30 → 2026-07-16

2026-03-30 → 2026-07-16

CANF Overview

CANF

Can-Fite BioPharma Ltd.

Last price

$3.23

●Trend Score?

0/4

●Stretch Score?

2/6

Regime: DowntrendVolatility: NormalOversold-leaning

Chart Summary

CANF is showing weaker bearish structure with some mixed stretch signals. RSI is 48.6 and neutral.

As of 2026-07-16 15:30:14 · Source: financialmodelingprep.com

Price · Overview

From 2026-03-30 → 2026-07-16

2026-03-30 → 2026-07-16

Market Benchmarks

S&P 500 Detail →

Updated: 7/16/2026, 3:21:10 PM · Benchmarks (FMP)

Latest Headlines · CANF

MyStockHarbor Briefing

Latest headlines on CANF

Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares · Neutral tone · Mixed / range

Open full CANF news page

globenewswire.com

7/14/2026

Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer

Why this matters: Patent allowance in Australia may strengthen Namodenoson's IP position, potentially supporting future market exclusivity in key cancer indications.

globenewswire.com

7/6/2026

Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027

Why this matters: Completion of patient enrolment for Phase 3 psoriasis trial signals progress; upcoming interim data could impact near-term sentiment and valuation.

globenewswire.com

7/1/2026

Wall Street is Watching These Biotechs

Why this matters: Watch trial outcomes and regulatory updates as Wall Street interest may increase volatility but fundamentals remain dependent on clinical progress.

Open Insights →Stock Pickers →

Fresh content

Read the latest stock market insights & trade ideas

Chart-based market insights, technical analysis write-ups and stock breakdowns from MyStockHarbor.

Analyze any stock

Search a ticker for its full breakdown, or scan for fresh ideas.

What's happening across MyStockHarbor

⛓️Bottlenecks

Where the market's choke points hide

🔎Pickers

Today's screened setups & breakouts

💡Insights

Fresh chart breakdowns, daily

🧠News

Headlines — uniquely scored & explained

📅Earnings

Beat, miss & surprise % — decoded

CANF Overview

CANF

Can-Fite BioPharma Ltd.

Last price

$3.23

●Trend Score?

0/4

●Stretch Score?

2/6

Regime: DowntrendVolatility: NormalOversold-leaning

Chart Summary

CANF is showing weaker bearish structure with some mixed stretch signals. RSI is 48.6 and neutral.

As of 2026-07-16 15:30:14 · Source: financialmodelingprep.com

Breakdown

?Learn more →

MA200

-36.68%

VWMA(20)

-20.46%

Stoch

Oversold

Earnings

Weak

ATR

Normal 1.10×

MACD

Bearish

RSI

Neutral

Volume

Normal 0.00×

Price · Overview

From 2026-03-30 → 2026-07-16

2026-03-30 → 2026-07-16

CANF Overview

CANF

Can-Fite BioPharma Ltd.

Last price

$3.23

●Trend Score?

0/4

●Stretch Score?

2/6

Regime: DowntrendVolatility: NormalOversold-leaning

Chart Summary

CANF is showing weaker bearish structure with some mixed stretch signals. RSI is 48.6 and neutral.

As of 2026-07-16 15:30:14 · Source: financialmodelingprep.com

Price · Overview

From 2026-03-30 → 2026-07-16

2026-03-30 → 2026-07-16

Market Benchmarks

S&P 500 Detail →

Updated: 7/16/2026, 3:21:10 PM · Benchmarks (FMP)

Latest Headlines · CANF

MyStockHarbor Briefing

Latest headlines on CANF

Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares · Neutral tone · Mixed / range

Open full CANF news page

globenewswire.com

7/14/2026

Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer

Why this matters: Patent allowance in Australia may strengthen Namodenoson's IP position, potentially supporting future market exclusivity in key cancer indications.

globenewswire.com

7/6/2026

Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027

Why this matters: Completion of patient enrolment for Phase 3 psoriasis trial signals progress; upcoming interim data could impact near-term sentiment and valuation.

globenewswire.com

7/1/2026

Wall Street is Watching These Biotechs

Why this matters: Watch trial outcomes and regulatory updates as Wall Street interest may increase volatility but fundamentals remain dependent on clinical progress.